Holen Sie sich die Stockscreener-App
0.7399
15.87%
-0.1396
Handel nachbörslich:
.77
0.0301
+4.07%
Schlusskurs vom Vortag:
$0.8795
Offen:
$0.8542
24-Stunden-Volumen:
787.01K
Relative Volume:
0.50
Marktkapitalisierung:
$22.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-1.0042
EPS:
-0.7368
Netto-Cashflow:
-
1W Leistung:
-23.80%
1M Leistung:
-29.53%
6M Leistung:
-33.94%
1J Leistung:
-88.21%
1-Tages-Spanne:
$0.7126
$0.90
1-Wochen-Bereich:
$0.7126
$0.9899
52-Wochen-Spanne:
$0.58
$8.30
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Vergleichen Sie CLDI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.7399 | 22.81M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - WSIL TV
Calidi Biotherapeutics to Showcase Cancer-Fighting Oncolytic Virus Platform on Bloomberg TV | CLDI Stock News - StockTitan
Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA - ACCESS Newswire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth With Strengthened Financial Position And Cutting-Edge Research - MENAFN.COM
Calidi Biotherapeutics Announces Commencement of - GlobeNewswire
Closing Figures Unveiled: Calidi Biotherapeutics Inc (CLDI) Drop -16.67, Closes at 1.05 - The Dwinnex
Calidi Biotherapeutics Initiates Recruitment for CLD-101 Clinical Trial Targeting High-Grade Glioma - Nasdaq
Can Multiple Doses Make This Brain Cancer Treatment More Effective? Northwestern Launches Next-Phase Trial - StockTitan
Calidi Biotherapeutics Inc (CLDI) rating initates by H.C. Wainwright - Knox Daily
Taking on analysts’ expectations and winning: Calidi Biotherapeutics Inc (CLDI) - SETE News
CLDI’s 2023 Market Dance: Up 13.04% – Time to Invest? - The InvestChronicle
A review of CLDI’s current quarter earnings predictions - US Post News
What Recent Market Trends Mean for Calidi Biotherapeutics Inc’s (CLDI) Stock - The News Heater
Calidi Biotherapeutics expands stock offering capacity - Investing.com India
Calidi Biotherapeutics expands stock offering capacity By Investing.com - Investing.com South Africa
Market Recap: Calidi Biotherapeutics Inc (CLDI)’s Positive Momentum, Closing at 1.32 - The Dwinnex
For Calidi Biotherapeutics Inc [CLDI], Analyst sees a rise to $11. What next? - The DBT News
Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Get in on Calidi Biotherapeutics Inc’s (CLDI) buy-in window today! - SETE News
Taking a Closer Look At Calidi Biotherapeutics Inc (CLDI) Following Its Recent Trade - Knox Daily
CLDI’s price-to-sales ratio: A comparative analysis with its peers - US Post News
CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com Australia
Calidi Biotherapeutics Bolsters Cash Balance and Terminates Standby Equity Purchase AgreementSAN DIEGO, January 28, 2025 – Calidi Biotherapeutics Inc. (NYSE American: CLDI) recently disclosed the ending cash balance amounting to approximately $ - Defense World
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - GlobeNewswire
Inside Calidi's Game-Changing Cancer Treatment Pipeline: Top Execs Reveal Next-Gen Therapies - StockTitan
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics Ends SEPA After Successful Fundraising - TipRanks
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement - GlobeNewswire
Cancer Biotech Raises $18.8M War Chest to Fast-Track Revolutionary Brain Cancer Treatment - StockTitan
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Why Calidi Biotherapeutics Inc (AMEX: CLDI) Is A Great Stock Pick For Momentum Investors - Stocks Register
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
CLDI stock touches 52-week low at $0.73 amid market challenges - Investing.com Australia
The Business Case For Buying Calidi Biotherapeutics Inc (AMEX: CLDI) Stock Now - Stocks Register
Calidi Biotherapeutics Announces Presentation of New Data - GlobeNewswire
Calidi Biotherapeutics to Present Breakthrough Cancer Treatment Platform at AACR 2025 Meeting - StockTitan
Calidi Biotherapeutics announces reverse stock split adjustment - Investing.com
Calidi Biotherapeutics Announces $4.25 Million Public Stock Offering - Defense World
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Refiles Consolidated Financial Statements After Reverse Stock Split - Defense World
Calidi Biotherapeutics Raises $4.25M Through Public Offering of Common Stock at $0.85 Per Share - StockTitan
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30% - Benzinga
Calidi Biotherapeutics slumps 29%, prices $4.25M stock offering - MSN
Calidi Biotherapeutics Announces Public Stock Offering Deal - TipRanks
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - The Bakersfield Californian
Calidi Biotherapeutics Raises $4.25M Through Public Offering to Advance Cancer Immunotherapy Platform - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
Kapitalisierung:
|
Volumen (24h):